<DOC>
	<DOC>NCT02988960</DOC>
	<brief_summary>This is a dose-escalation study designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of ABBV-927, and to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RPTD) for ABBV-927 when administered as monotherapy or as combination therapy with nivolumab in participants with advanced solid tumors.</brief_summary>
	<brief_title>A Study of ABBV-927, an Immunotherapy, in Participants With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Participant has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1. Participants have adequate bone marrow, kidney and liver function. Participants in all monotherapy arms must have an advanced solid tumor that has progressed on standard therapies known to provide clinical benefit or the participants are intolerant to such therapies. Participants in all combination therapy arms must have an advanced solid tumor for which the indicated standard of care is nivolumab. Active or prior documented autoimmune disease in the last 2 years. Current or prior use of immunosuppressive medication within 14 days prior to the first dose (with certain exceptions). History of primary immunodeficiency, bone marrow transplantation, chronic lymphocytic leukemia, solid organ transplantation, or previous clinical diagnosis of tuberculosis. Prior grade greater than or equal to 3 immunemediated neurotoxicity or pneumonitis while receiving immunotherapy. Known uncontrolled malignancy of the central nervous system</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Pancreatic adenocarcinoma</keyword>
	<keyword>Non-small cell lung cancer (NSCLC)</keyword>
	<keyword>Squamous cell carcinoma of the head and neck (SCCHN)</keyword>
	<keyword>Nivolumab</keyword>
	<keyword>Cutaneous melanoma</keyword>
	<keyword>Advanced solid tumor</keyword>
	<keyword>Cancer</keyword>
</DOC>